Skip to content

Price / book at other companies

Eli Lilly logo
Eli LillyLLY
26.3×-20.7×
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
1.5×-3.9×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
25.2×+15.2×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
22.1×+11.8×
ALN
Alnylam PharmaceuticalsALNY
40.8×-41.2×
Beam Therapeutics logo
Beam TherapeuticsBEAM
2.1×+0.4×

Other financials

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Cash & equivalents$544.6M+124%
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation

See full
Market cap$1.14B+13.0%
Enterprise value$615.92M-22.3%
P/S15.1×-12.2×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-53.7%
Debt / equity-0.1×
Current ratio11.3×+8.3×

Where this comes from

Calculated from Wave Life Sciences’s reported figures.

Based on the most recent quarter.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Wave Life Sciences's price / book?
Wave Life Sciences (WVE) reported price / book of 2.7× in Q1 2026.
How has Wave Life Sciences's price / book changed year-over-year?
Wave Life Sciences's price / book decreased by 63.1% year-over-year, from 7.2× to 2.7×.
What is the long-term trend for Wave Life Sciences's price / book?
Over 4 years (2020 to 2025), Wave Life Sciences's price / book has grown at a 2.2% compound annual growth rate (CAGR), from 5.6× to 6.1×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.